The genetics of innate immunity sensors and human disease

International Reviews of Immunology

Volumn 32, Issue 2, 2013, Pages 157-208

  Pothlichet, Julien ^a,b   Quintana Murci, Lluis ^a,b  

^a INSTITUT PASTEUR   (France)

^b CNRS   (France)

Author keywords

C type lectin receptors (CLRs); Cytosolic DNA sensors (CDSs); NOD like receptors (NLRs); RIG I like receptors (RLRs); Single nucleotide polymorphisms (SNPs); Toll like receptors (TLRs)

Indexed keywords

LECTIN RECEPTOR; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

AUTOIMMUNE DISEASE; GENETIC ASSOCIATION; HUMAN; IMMUNOGENETICS; INNATE IMMUNITY; MOLECULAR SENSOR; MYCOSIS; NONHUMAN; PARASITOSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS INFECTION;

ANIMALS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNITY, INNATE; POLYMORPHISM, GENETIC; RECEPTORS, PATTERN RECOGNITION;

EID: 84876134299     PISSN: 08830185     EISSN: 15635244     Source Type: Journal    
DOI: 10.3109/08830185.2013.777064     Document Type: Review

References (406)

1. Janeway CA, Jr.,Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216. (Pubitemid 34293424)
2. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988;52:269-279.
3. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-983. (Pubitemid 26336801)
4. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011;34:637-650.
5. Kawai T, Akira S.The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-384.
6. Loo YM, GaleM, Jr. Immune signaling by RIG-I-like receptors. Immunity 2011;34:680-692.
7. Elinav E, Strowig T, Henao-Mejia J, Flavell RA. Regulation of the antimicrobial response by NLR proteins. Immunity 2011;34:665-679.
8. Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature 2009;458:514-518.
9. Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol 2010;11:395-402.
10. Osorio F, Reis e Sousa C.Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity 2011;34:651-664.
11. Sancho D, Reis e Sousa C. Signaling bymyeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol 2012;30:491-529.
12. Kaufmann SH. Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. N Engl JMed 2005;353:2423-2426. (Pubitemid 41770161)
13. Comstock GW. Tuberculosis in twins: a re-analysis of the Prophit survey. Am Rev Respir Dis 1978;117:621-624. (Pubitemid 8334970)
14. Misch EA, Berrington WR, Vary JC, Jr., Hawn TR. Leprosy and the human genome. Microbiol Mol Biol Rev 2010;74:589-620.
15. Herndon CN, Jennings RG. A twin-family study of susceptibility to poliomyelitis. Am J Hum Genet 1951;3:17-46.
16. Lin TM, Chen CJ, Wu MM, et al. Hepatitis B virus markers in Chinese twins. Anticancer Res 1989;9:737-741. (Pubitemid 19194309)
17. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl JMed 1988;318:727-732. (Pubitemid 18090256)
18. Allison AC. Protection afforded by sickle-cell trait against subtertian malareal infection. Br Med J 1954;1:290-294.
19. Hill AV.The immunogenetics of resistance tomalaria. Proc AssocAmPhysicians 1999;111:272-277.
20. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol 2011;29: 447-491.
21. Barreiro LB, Quintana-Murci L. Fromevolutionary genetics to human immunology: how selection shapes host defence genes. Nat Rev Genet 2010;11:17-30.
22. Quintana-Murci L, Alcais A, Abel L, Casanova JL. Immunology in natura: clinical, epidemiological and evolutionary genetics of infectious diseases. Nat Immunol 2007;8:1165-1171. (Pubitemid 350011752)
23. Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science 2007;317:617-619. (Pubitemid 47229951)
24. Casanova JL, Fieschi C, Zhang SY, Abel L. Revisiting human primary immunodeficiencies. J Intern Med 2008;264:115-127. (Pubitemid 351965489)
25. Notarangelo LD, Casanova JL. Primary immunodeficiencies: increasing market share. Curr Opin Immunol 2009;21:461-465.
26. Hill AV.The genomics and genetics of human infectious disease susceptibility. Annu RevGenomics HumGenet 2001;2:373-400. (Pubitemid 35265012)
27. Hill AV. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet 2006;40:469-486. (Pubitemid 44956793)
28. Chapman SJ, Hill AV. Human genetic susceptibility to infectious disease. Nat Rev Genet 2012;13:175-188.
29. Vannberg FO, Chapman SJ, Hill AV. Human genetic susceptibility to intracellular pathogens. Immunol Rev 2011;240:105-116.
30. Fornarino S, Laval G, Barreiro LB, et al. Evolution of the TIR domain-containing adaptors in humans: swinging between constraint and adaptation.Mol Biol Evol 2011;28:3087-3097.
31. Barreiro LB, Ben-Ali M, Quach H, et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet 2009;5:e1000562.
32. Vasseur E, Boniotto M, Patin E, et al. The evolutionary landscape of cytosolic microbial sensors in humans. AmJ HumGenet 2012;91:27-37.
33. Vasseur E, Patin E, Laval G, et al.The selective footprints of viral pressures at the human RIG-I-like receptor family. HumMol Genet 2011;20:4462-4474.
34. Mancuso G, Gambuzza M, Midiri A, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. Nat Immunol 2009;10:587-594.
35. Guan Y, Ranoa DR, Jiang S, et al. Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling. J Immunol 2010;184:5094-5103.
36. Ferwerda B,McCall MB,Alonso S, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration ofmodern humans. Proc Natl Acad Sci USA 2007;104:16645-16650. (Pubitemid 350211070)
37. Agnese DM, Calvano JE, Hahm SJ, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002;186:1522-1525. (Pubitemid 35286126)
38. Lorenz E,Mira JP, Frees KL, Schwartz DA. Relevance ofmutations in the TLR4 receptor in patients with gram-negative septic shock. Arch InternMed 2002;162:1028-1032. (Pubitemid 34492532)
39. Barber RC,Aragaki CC, Rivera-Chavez FA, et al. TLR4 andTNF-alpha polymorphisms are associated with an increased risk for severe sepsis following burn injury. JMed Genet 2004;41:808-813. (Pubitemid 39524306)
40. Faber J, Henninger N, Finn A, et al. A toll-like receptor 4 variant is associated with fatal outcome in children with invasive meningococcal disease. Acta Paediatr 2009;98:548-552.
41. Faber J,Meyer CU, Gemmer C, et al. Human toll-like receptor 4mutations are associated with susceptibility to invasivemeningococcal disease in infancy. Pediatr Infect Dis J 2006;25:80-81. (Pubitemid 43361484)
42. Akil I, Ozkinay F, Onay H, et al. Assessment of Toll-like receptor-4 gene polymorphism on pyelonephritis and renal scar. Int J Immunogenet 2012;39:303-307.
43. Vuononvirta J, Toivonen L, Grondahl-Yli-Hannuksela K, et al. Nasopharyngeal bacterial colonization and gene polymorphisms ofmannose-binding lectin and toll-like receptors 2 and 4 in infants. PLoS One 2011;6:e26198.
44. West TE, Chierakul W, ChantratitaN, et al. Toll-like receptor 4 region genetic variants are associated with susceptibility to melioidosis. Genes Immun 2012;13:38-46.
45. Feterowski C, Emmanuilidis K, Miethke T, et al. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 2003;109: 426-431. (Pubitemid 36783269)
46. Jessen KM, Lindboe SB, Petersen AL, et al. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome fromGramnegative sepsis. BMC Infect Dis 2007;7:108.
47. Child NJ, Yang IA, Pulletz MC, et al. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem Soc Trans 2003;31:652-653. (Pubitemid 36750749)
48. Hawn TR, Verbon A, Janer M, et al. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc Natl Acad Sci USA 2005;102:2487-2489. (Pubitemid 40279403)
49. Krutzik SR, Ochoa MT, Sieling PA, et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. NatMed 2003;9:525-532. (Pubitemid 36597097)
50. Drage MG, Pecora ND, Hise AG, et al. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol 2009;258:29-37.
51. Kleinnijenhuis J, Oosting M, Joosten LA, et al. Innate immune recognition of Mycobacterium tuberculosis. Clin Dev Immunol 2011;2011:405310.
52. Saiga H, Shimada Y, Takeda K. Innate immune effectors in mycobacterial infection. Clin Dev Immunol 2011;2011:347594.
53. Johnson CM, Lyle EA, Omueti KO, et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007;178:7520-7524. (Pubitemid 46898019)
54. Wong SH, Gochhait S,Malhotra D, et al. Leprosy and the adaptation of human toll-like receptor 1. PLoS Path 2010;6:e1000979.
55. Schuring RP, Hamann L, Faber WR, et al. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J Infect Dis 2009;199:1816-1819.
56. Bochud PY,Hawn TR, SiddiquiMR, et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J Infect Dis 2008;197:253-261. (Pubitemid 351263444)
57. Ogus AC, Yoldas B, Ozdemir T, et al.The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004;23:219-223. (Pubitemid 38195506)
58. Ma X, Liu Y, Gowen BB, et al. Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2007;2:e1318.
59. Yim JJ, Lee HW, Lee HS, et al. The association between microsatellite polymorphisms in intron II of the human Toll-like receptor 2 gene and tuberculosis among Koreans. Genes Immun 2006;7:150-155. (Pubitemid 43336057)
60. Chen YC, Hsiao CC, Chen CJ, et al. Toll-like receptor 2 gene polymorphisms, pulmonary tuberculosis, and natural killer cell counts. BMCMed Genet 2010;11:17.
61. Caws M,Thwaites G, Dunstan S, et al.The influence of host and bacterial genotype on the development of disseminated disease withMycobacterium tuberculosis. PLoS Path 2008;4:e1000034.
62. Dalgic N, TekinD, Kayaalti Z, et al. Arg753Gln polymorphism of the human Toll-like receptor 2 gene from infection to disease in pediatric tuberculosis. Hum Immunol 2011;72:440-445.
63. Najmi N, Kaur G, Sharma SK, Mehra NK. Human Toll-like receptor 4 polymorphisms TLR4 Asp299Gly and Thr399Ile influence susceptibility and severity of pulmonary tuberculosis in the Asian Indian population. Tissue Antigens 2010;76:102-109.
64. Uciechowski P, Imhoff H, Lange C, et al. Susceptibility to tuberculosis is associated with TLR1 polymorphisms resulting in a lack of TLR1 cell surface expression. J Leukoc Biol 2011;90: 377-388.
65. Davila S, Hibberd ML, Hari Dass R, et al. Genetic association and expression studies indicate a role of toll-like receptor 8 in pulmonary tuberculosis. PLoS Genet 2008;4:e1000218.
66. Velez DR, Wejse C, Stryjewski ME, et al. Variants in toll-like receptors 2 and 9 influence susceptibility to pulmonary tuberculosis in Caucasians, African-Americans, andWest Africans.Hum Genet 2010;127:65-73.
67. Kobayashi K, Yuliwulandari R, YanaiH, et al. Association of TLR polymorphisms with development of tuberculosis in Indonesian females. Tissue Antigens 2012;79:190-197.
68. Schroder NW, Diterich I, Zinke A, et al. Heterozygous Arg753Gln polymorphism of human TLR-2 impairs immune activation by Borrelia burgdorferi and protects from late stage Lyme disease. J Immunol 2005;175:2534-2540. (Pubitemid 41113865)
69. Hawn TR, Verbon A, Lettinga KD, et al. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J Exp Med 2003;198:1563-1572. (Pubitemid 37467170)
70. Merx S, ZimmerW,Neumaier M, Ahmad-Nejad P. Characterization and functional investigation of single nucleotide polymorphisms (SNPs) in the human TLR5 gene. HumMutat 2006;27:293.
71. Bourgeois C, Kuchler K. Fungal pathogens-a sweet and sour treat for toll-like receptors. Front Cell InfectMicrobiol 2012;2:142.
72. Plantinga TS, Johnson MD, Scott WK, et al. Toll-like receptor 1 polymorphisms increase susceptibility to candidemia. J Infect Dis 2012;205:934-943.
73. Van der Graaf CA, Netea MG, Morre SA, et al. Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 2006;17:29-34.
74. Kesh S, Mensah NY, Peterlongo P, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann NY Acad Sci 2005;1062:95-103.
75. Bochud PY, Chien JW,Marr KA, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stemcell transplantation. N Engl JMed 2008;359:1766-1777.
76. Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis 2008;197:618-621. (Pubitemid 351321541)
77. de Boer MG, Jolink H, Halkes CJ, et al. Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation. PLoS One 2011;6:e18403.
78. Ranjith-Kumar CT, Miller W, Sun J, et al. Effects of single nucleotide polymorphisms on Toll-like receptor 3 activity and expression in cultured cells. J Biol Chem 2007;282:17696-17705. (Pubitemid 47100325)
79. NahumA, Dadi H, Bates A, Roifman CM. The L412F variant of Toll-like receptor 3 (TLR3) is associated with cutaneous candidiasis, increased susceptibility to cytomegalovirus, and autoimmunity. J Allergy Clin Immunol 2011;127:528-531.
80. Nahum A, Dadi H, Bates A, Roifman CM. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity. Autoimmun Rev 2012;11:341-347.
81. Carvalho A, De Luca A, Bozza S, et al. TLR3 essentially promotes protective class I-restrictedmemoryCD8(+) T-cell responses toAspergillus fumigatus inhematopoietic transplanted patients.Blood 2012;119:967-977.
82. Akira S,Uematsu S, Takeuchi O. Pathogen recognition and innateimmunity. Cell 2006;124:783-801.
83. Zhang SY, Jouanguy E,Ugolini S, et al. TLR3 deficiency in patientswith herpes simplex encephalitis. Science 2007;317:1522-1527. (Pubitemid 47417427)
84. Guo Y, Audry M, Ciancanelli M, et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J Exp Med 2011;208:2083-2098.
85. Sironi M, Biasin M, Cagliani R, et al. A common polymorphism in TLR3 confers natural resistance to HIV-1 infection. J Immunol 2012;188:818-823.
86. Askar E, Bregadze R,Mertens J, et al. TLR3 gene polymorphisms and liver diseasemanifestations in chronic hepatitis C. JMed Virol 2009;81:1204-1211.
87. Qian F, Bolen CR, Jing C, et al. Impaired TLR3-mediated immune responses from macrophages of patients chronically infected with Hepatitis C virus. Clin Vaccine Immunol 2013;20:146-155.
88. Al-Qahtani A, Al-Ahdal M, Abdo A, et al. Toll-like receptor 3 polymorphism and its association with hepatitis B virus infection in Saudi Arabian patients. JMed Virol 2012;84:1353-1359.
89. Nuolivirta K, He Q, Vuononvirta J, et al. Toll-like receptor 3 L412F polymorphisms in infants with bronchiolitis and postbronchiolitis wheezing. Pediatr Infect Dis J 2012;31:920-923.
90. Lee SO, Brown RA, Razonable RR. Association between a functional polymorphism in Toll-like receptor 3 and chronic hepatitis C in liver transplant recipients. Transpl Infect Dis 2012.
91. Hidaka F,Matsuo S,Muta T, et al. A missensemutation of the Toll-like receptor 3 gene in a patient with influenza-associated encephalopathy. Clin Immunol 2006;119:188-194.
92. Oh DY, Baumann K, Hamouda O, et al. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS 2009;23:297-307.
93. Oh DY, Taube S, Hamouda O, et al. A functional toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis 2008;198:701-709.
94. Bochud PY,HersbergerM, Taffe P, et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007;21:441-446.
95. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, et al. Influence of the Toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr 2008;49:128-135.
96. Ovsyannikova IG, Haralambieva IH, Vierkant RA, et al. The role of polymorphisms in Toll-like receptors and their associated intracellular signaling genes inmeasles vaccineimmunity.HumGenet 2011;130:547-561.
97. Bochud PY, Magaret AS, Koelle DM, et al. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J Infect Dis 2007;196:505-509. (Pubitemid 47206095)
98. Kijpittayarit S, Eid AJ, Brown RA, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin Infect Dis 2007;44:1315-1320. (Pubitemid 46717293)
99. Kang SH, Abdel-Massih RC, Brown RA, et al.Homozygosity for the toll-like receptor 2 R753Q singlenucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012;205:639-646.
100. TalG,Mandelberg A,Dalal I, et al. Association between common Toll-like receptor 4mutations and severe respiratory syncytial virus disease. J Infect Dis 2004;189:2057-2063. (Pubitemid 38692286)
101. Paulus SC,HirschfeldAF, Victor RE, et al.Commonhuman Toll-like receptor 4 polymorphisms-role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin Immunol 2007;123:252-257. (Pubitemid 46818131)
102. CobanC,Horii T, Akira S, Ishii KJ.TLR9 andendogenous adjuvants of the wholeblood-stagemalaria vaccine. Expert Rev Vaccines 2010;9:775-784.
103. Coban C, Igari Y, Yagi M, et al. Immunogenicity of whole-parasite vaccines against Plasmodium falciparuminvolvesmalarial hemozoin and host TLR9. Cell HostMicrobe 2010;7:50-61.
104. Tarleton RL. Immune system recognition of Trypanosoma cruzi. Curr Opin Immunol 2007;19:430-434. (Pubitemid 47284855)
105. Oliveira AC, Peixoto JR, de Arruda LB, et al. Expression of functional TLR4 confers proinflammatory responsiveness to Trypanosoma cruzi glycoinositolphospholipids and higher resistance to infection with T. cruzi. J Immunol 2004;173:5688-5696. (Pubitemid 39392157)
106. Esposito S, Molteni CG, Zampiero A, et al. Role of polymorphisms of toll-like receptor (TLR) 4, TLR9, toll-interleukin 1 receptor domain containing adaptor protein (TIRAP) and FCGR2A genes in malaria susceptibility and severity in Burundian children. Malar J 2012;11: 196.
107. Sawian CE, Lourembam SD, Banerjee A, Baruah S. Polymorphisms and expression of TLR4 and 9 inmalaria in two ethnic groups of Assam, northeast India. Innate Immun 2012.
108. Zakeri S, Pirahmadi S,Mehrizi AA, Djadid ND. Genetic variation of TLR-4, TLR-9 and TIRAP genes in Iranianmalaria patients.Malar J 2011;10:77.
109. Mockenhaupt FP, Cramer JP, Hamann L, et al. Toll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci USA 2006;103:177-182. (Pubitemid 43076124)
110. Weitzel T, Zulantay I, Danquah I, et al. Mannose-binding lectin and Toll-like receptor polymorphisms and Chagas disease in Chile. AmJ TropMed Hyg 2012;86:229-232.
111. Broen JC, Bossini-Castillo L, van Bon L, et al. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators. Arthritis Rheum 2012;64:264-271.
112. Lee YH, Lee HS, Choi SJ, et al. Associations between TLR polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis. Clin Exp Rheumatol 2012;30:262-265.
113. Kawasaki A, Furukawa H, Kondo Y, et al. TLR7 single-nucleotide polymorphisms in the 3' untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis ResTher 2011;13:R41.
114. Shen N, Fu Q, Deng Y, et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci USA 2010;107:15838-15843.
115. Dubois PC, Trynka G, Franke L, et al.Multiple common variants for celiac disease influencing immune gene expression. Nat Genet 2010;42:295-302.
116. Abad C, Gonzalez-Escribano MF, Diaz-Gallo LM, et al. Association of Toll-like receptor 10 and susceptibility to Crohn's disease independent of NOD2. Genes Immun 2011;12:635-642.
117. Morgan AR, Lam WJ, Han DY, et al. Genetic variation within TLR10 is associated with Crohn's disease in a New Zealand population. HumImmunol 2012;73:416-420.
118. Veltkamp M, van Moorsel CH, Rijkers GT, et al. Genetic variation in the Toll-like receptor gene cluster (TLR10-TLR1-TLR6) influences disease course in sarcoidosis. Tissue Antigens 2012;79: 25-32.
119. Kutikhin AG. Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol 2011;72:1095-1116.
120. Lazarus R, Raby BA, Lange C, et al. TOLL-like receptor 10 genetic variation is associatedwith asthma in two independent samples. Am J Respir Crit CareMed 2004;170:594-600. (Pubitemid 39202199)
121. Qian FH, Zhang Q, Zhou LF, et al. Polymorphisms in the toll-like receptor 2 subfamily and risk of asthma: a case-control analysis in a Chinese population. J Investig Allergol Clin Immunol 2010;20:340-346.
122. Eder W, Klimecki W, Yu L, et al. Toll-like receptor 2 as amajor gene for asthma in children of European farmers. J Allergy Clin Immunol 2004;113:482-488. (Pubitemid 38338954)
123. Kormann MS, Depner M, Hartl D, et al. Toll-like receptor heterodimer variants protect from childhood asthma. J Allergy Clin Immunol 2008;122:86-92, 92 e81-88.
124. Theodoropoulos GE, Saridakis V, Karantanos T, et al. Toll-like receptors gene polymorphismsmay confer increased susceptibility to breast cancer development. Breast 2012;21:534-538.
125. Junjie X, Songyao J,Minmin S, et al. The association between Toll-like receptor 2 single-nucleotide polymorphisms and hepatocellular carcinoma susceptibility. BMC Cancer 2012;12:57.
126. He JF, Jia WH, Fan Q, et al. Genetic polymorphisms of TLR3 are associated with Nasopharyngeal carcinoma risk in Cantonese population. BMC Cancer 2007;7:194.
127. Yang ZH, Dai Q, Gu YJ, et al. Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma. Cancer Sci 2012;103:653-658.
128. Song C, Chen LZ, Zhang RH, et al. Functional variant in the 3'-untranslated region of Toll-like receptor 4 is associated with nasopharyngeal carcinoma risk. Cancer Biol Ther 2006;5:1285-1291. (Pubitemid 44772253)
129. Gast A, Bermejo JL, Claus R, et al. Association of inherited variation in Toll-like receptor genes with malignantmelanoma susceptibility and survival. PLoS One 2011;6:e24370.
130. Miedema KG, Tissing WJ, Te Poele EM, et al. Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease. Leukemia 2012;26:1203-1210.
131. O'Neill LA, Bowie AG.Thefamily of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007;7:353-364. (Pubitemid 46674493)
132. Beutler B, Hoebe K, Georgel P, et al. Genetic analysis of innate immunity: TIR adapter proteins in innate and adaptive immune responses.Microbes Infect 2004;6:1374-1381. (Pubitemid 41110580)
133. O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008;226:10-18.
134. Kenny EF, O'Neill LA. Signalling adaptors used by Toll-like receptors: an update. Cytokine 2008;43:342-349.
135. Carty M, Goodbody R, Schroder M, et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat Immunol 2006;7:1074-1081. (Pubitemid 44420652)
136. Peng J, Yuan Q, Lin B, et al. SARM inhibits both TRIF-andMyD88-mediated AP-1 activation. Eur J Immunol 2010;40:1738-1747.
137. Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol 2012;13:916-924.
138. Isnardi I, Ng YS, Srdanovic I, et al. IRAK-4-and MyD88-dependent pathways are essential for the removal of developing autoreactive B cells in humans. Immunity 2008;29:746-757.
139. Itoh H, TatematsuM,Watanabe A, et al. UNC93B1 physically associates with human TLR8 and regulates TLR8-mediated signaling. PLoS One 2011;6:e28500.
140. Shah JA, Vary JC, Chau TT, et al. Human TOLLIP regulates TLR2 and TLR4 signaling and its polymorphisms are associated with susceptibility to tuberculosis. J Immunol 2012;189:1737-1746.
141. Picard C, Casanova JL, Puel A. Infectious diseases in patients with IRAK-4,MyD88, NEMO, or IkappaBalpha deficiency. ClinMicrobiol Rev 2011;24:490-497.
142. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008;321:691-696.
143. Picard C, Puel A, BonnetM, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003;299:2076-2079. (Pubitemid 36383736)
144. Ku CL, von Bernuth H, Picard C, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007;204:2407-2422. (Pubitemid 47529326)
145. Perez de Diego R, Sancho-Shimizu V, Lorenzo L, et al. Human TRAF3 adaptormolecule deficiency leads to impaired Toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 2010;33:400-411.
146. Herman M, Ciancanelli M, Ou YH, et al. Heterozygous TBK1mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J ExpMed 2012;209:1567-1582.
147. Sancho-Shimizu V, Perez deDiego R, Lorenzo L, et al.Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J Clin Invest 2011;121:4889-4902.
148. Lafaille FG, Pessach IM, Zhang SY, et al. Impaired intrinsic immunity to HSV-1 in human iPSCderived TLR3-deficient CNS cells. Nature 2012;491:769-773.
149. Casrouge A, Zhang SY, Eidenschenk C, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006;314:308-312. (Pubitemid 44571977)
150. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007;39:523-528. (Pubitemid 46514767)
151. Hamann L,KumpfO, Schuring RP, et al. Lowfrequency of the TIRAP S180L polymorphism in Africa, and its potential role inmalaria, sepsis, and leprosy. BMCMed Genet 2009;10:65.
152. Nejentsev S,Thye T, Szeszko JS, et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nat Genet 2008;40:261-262; author reply 262-263. (Pubitemid 351311779)
153. Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012;44:676-680.
154. Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. FEBS J 2005;272:6179-6217. (Pubitemid 41815610)
155. Weis WI, Drickamer K. Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem 1996;65:441-473. (Pubitemid 26250616)
156. Gringhuis SI, Kaptein TM, Wevers BA, et al. Dectin-1 is an extracellular pathogen sensor for the induction and processing of IL-1beta via a noncanonical caspase-8 inflammasome. Nat Immunol 2012;13:246-254.
157. Ferwerda B, Ferwerda G, Plantinga TS, et al.Human dectin-1 deficiency andmucocutaneous fungal infections. N Engl JMed 2009;361:1760-1767.
158. Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9mutation in a family with susceptibility to fungal infections. N Engl JMed 2009;361:1727-1735.
159. Robinson MJ, Sancho D, Slack EC, et al. Myeloid C-type lectins in innate immunity. Nat Immunol 2006;7:1258-1265. (Pubitemid 46111243)
160. van den Berg LM, Gringhuis SI, Geijtenbeek TB. An evolutionary perspective on C-type lectins in infection and immunity. Ann NY Acad Sci 2012;1253:149-158.
161. Puel A, Cypowyj S,Marodi L, et al. Inborn errors of human IL-17 immunity underlie chronicmucocutaneous candidiasis. Curr Opin Allergy Clin Immunol 2012;12:616-622.
162. Chai LY, de Boer MG, van der Velden WJ, et al. The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis 2011;203:736-743.
163. Cunha C, Di Ianni M, Bozza S, et al. Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient-and donor-dependent mechanisms of antifungal immunity. Blood 2010;116:5394-5402.
164. Plantinga TS, van der Velden WJ, Ferwerda B, et al. Early stop polymorphism in human DECTIN-1 is associated with increased candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009;49:724-732.
165. Barreiro LB, Neyrolles O, Babb CL, et al. Promoter variation in the DC-SIGN-encoding gene CD209 is associated with tuberculosis. PLoSMed 2006;3:e20.
166. Sakuntabhai A, Turbpaiboon C, Casademont I, et al. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005;37:507-513. (Pubitemid 40617279)
167. Martin MP, Lederman MM,HutchesonHB, et al. Association ofDC-SIGN promoter polymorphism with increased risk for parenteral, but notmucosal, acquisition of human immunodeficiency virus type 1 infection. J Virol 2004;78:14053-14056. (Pubitemid 39612803)
168. Vannberg FO, Chapman SJ, Khor CC, et al. CD209 genetic polymorphism and tuberculosis disease. PLoS One 2008;3:e1388.
169. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms inmultiple sclerosis. Nature 2011;476:214-219.
170. Burgdorf S, Kautz A, Bohnert V, et al. Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science 2007;316:612-616. (Pubitemid 46683149)
171. Largent BL,Walton KM, Hoppe CA, et al. Carbohydrate-specific adhesion of alveolarmacrophages tomannose-derivatized surfaces. J Biol Chem 1984;259:1764-1769. (Pubitemid 14146564)
172. Chieppa M, Bianchi G, Doni A, et al. Cross-linking of the mannose receptor on monocytederived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 2003;171:4552-4560. (Pubitemid 37310570)
173. Chavele KM, Martinez-Pomares L, Domin J, et al. Mannose receptor interacts with Fc receptors and is critical for the development of crescentic glomerulonephritis in mice. J Clin Invest 2010;120:1469-1478.
174. Zhang J, Tachado SD, Patel N, et al. Negative regulatory role ofmannose receptors on human alveolarmacrophage proinflammatory cytokine release in vitro. J Leukoc Biol 2005;78:665-674. (Pubitemid 41292089)
175. Royer PJ, EmaraM, Yang C, et al.Themannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity. J Immunol 2010;185:1522-1531.
176. Kamatani Y,Matsuda K, Okada Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010;42:210-215.
177. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007;39:857-864. (Pubitemid 47018195)
178. Wu X, Li J, Chen C, et al. Involvement of CLEC16A in activation of astrocytes after LPS treated. Neurochem Res 2012;37:5-14.
179. Kim S, Wairkar YP, Daniels RW, DiAntonio A. The novel endosomal membrane protein Ema interacts with the class C Vps-HOPS complex to promote endosomal maturation. J Cell Biol 2010;188:717-734.
180. Hakonarson H, Grant SF, Bradfield JP, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007;448:591-594. (Pubitemid 47206935)
181. Ramasamy A, Curjuric I, Coin LJ, et al. A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order. J Allergy Clin Immunol 2011;128:996-1005.
182. Mells GF, Floyd JA,Morley KI, et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 2011;43:329-332.
183. Plagnol V, Howson JM, Smyth DJ, et al. Genome-wide association analysis of autoantibody positivity in type 1 diabetes cases. PLoS Genet 2011;7:e1002216.
184. Cooper JD, Smyth DJ, Smiles AM, et al.Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008;40:1399-1401.
185. De Jager PL, Jia X, Wang J, et al.Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as newmultiple sclerosis susceptibility loci. Nat Genet 2009;41:776-782.
186. Skinningsrud B, Lie BA, Husebye ES, et al. A CLEC16A variant confers risk for juvenile idiopathic arthritis and anti-cyclic citrullinated peptide antibody negative rheumatoid arthritis. Ann Rheum Dis 2010;69:1471-1474.
187. Kerrigan AM, Brown GD. Syk-coupled C-type lectin receptors that mediate cellular activation via single tyrosine based activationmotifs. Immunol Rev 2010;234:335-352.
188. PapatriantafyllouM. T cells: the MALT1 switch in autoimmunity. Nat Rev Immunol 2012;12:807.
189. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246-252.
190. Franke A,McGovern DP, Barrett JC, et al. Genome-widemeta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
191. McGovern DP, Gardet A, Torkvist L, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet 2010;42:332-337.
192. Barrett JC, Lee JC, Lees CW, et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009;41:1330-1334.
193. Evans DM, Spencer CC, Pointon JJ, et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 2011;43:761-767.
194. Imamura M, Maeda S, Yamauchi T, et al. A single-nucleotide polymorphism in ANK1 is associated with susceptibility to type 2 diabetes in Japanese populations. Hum Mol Genet 2012;21: 3042-3049.
195. Parsa A, Chang YP, Kelly RJ, et al.Hypertrophy-associated polymorphisms ascertained in a founder cohort applied to heart failure risk andmortality. Clin Transl Sci 2011;4:17-23.
196. Teslovich TM,Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-713.
197. Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition. Nat Immunol 2011;12:121-128.
198. Tschopp J, Martinon F, Burns K. NALPs: a novel protein family involved in inflammation. Nat Rev Mol Cell Biol 2003;4:95-104. (Pubitemid 36172693)
199. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-265.
200. Appenrodt B, Grunhage F,GentemannMG, et al.Nucleotide-binding oligomerizationdomain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology 2010;51:1327-1333.
201. Nischalke HD, Berger C, Aldenhoff K, et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associatedwith increased risk for spontaneous bacterial peritonitis inliver cirrhosis. J Hepatol 2011;55:1010-1016.
202. Zhang FR, Huang W, Chen SM, et al. Genomewide association study of leprosy. N Engl J Med 2009;361:2609-2618.
203. BerringtonWR,MacdonaldM, Khadge S, et al. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J Infect Dis 2010;201:1422-1435.
204. Grant AV, Alter A,Huong NT, et al. Crohn's disease susceptibility genes are associated with Leprosy in the Vietnamese population. J Infect Dis 2012;206:1763-1767.
205. Schenk M, Krutzik SR, Sieling PA, et al. NOD2 triggers an interleukin-32-dependent human dendritic cell programin leprosy. NatMed 2012;18:555-563.
206. Hoffman HM, Brydges SD. Genetic andmolecular basis of inflammasome-mediated disease. J Biol Chem 2011;286:10889-10896.
207. Chen G, Shaw MH, Kim YG, Nunez G. NOD-like receptors: role in innate immunity and inflammatory disease. Annu Rev Pathol 2009;4:365-398.
208. Tanabe T, Chamaillard M, Ogura Y, et al. Regulatory regions and critical residues of NOD2 involved inmuramyl dipeptide recognition. EMBO J 2004;23:1587-1597. (Pubitemid 38579519)
209. Chamaillard M, Philpott D, Girardin SE, et al. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc Natl Acad Sci USA 2003;100:3455-3460. (Pubitemid 36356605)
210. Miceli-Richard C, Lesage S, Rybojad M, et al. CARD15 mutations in Blau syndrome. Nat Genet 2001;29:19-20. (Pubitemid 32801800)
211. Ogura Y, Bonen DK, Inohara N, et al. A frameshiftmutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606. (Pubitemid 32531409)
212. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603. (Pubitemid 32531408)
213. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008;8:458-466. (Pubitemid 351733422)
214. Economou M, Trikalinos TA, Loizou KT, et al. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393-2404. (Pubitemid 40039371)
215. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007;39:207-211. (Pubitemid 46184351)
216. Kenny EE,Pe'er I,KarbanA, et al.Agenome-wide scan of Ashkenazi JewishCrohn's disease suggests novel susceptibility loci. PLoS Genet 2012;8:e1002559.
217. McGovern DP, Jones MR, Taylor KD, et al. Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn's disease. HumMol Genet 2010;19:3468-3476.
218. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-962.
219. Raelson JV, Little RD, Ruether A, et al. Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci. Proc Natl Acad Sci USA 2007;104:14747-14752. (Pubitemid 350003214)
220. Julia A, Domenech E, Ricart E, et al. A genome-wide association study on a southern European population identifies a new Crohn's disease susceptibility locus at RBX1-EP300. Gut 2012.
221. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 2007;39:596-604. (Pubitemid 46676115)
222. ConsortiumWTCC.Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007;447:661-678.
223. Villani AC, Lemire M, Fortin G, et al. Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 2009;41:71-76.
224. Spritz RA,Gowan K, BennettDC, Fain PR.Novel vitiligo susceptibility loci on chromosomes 7 (AIS2) and 8 (AIS3), confirmation of SLEV1 on chromosome 17, and their roles in an autoimmune diathesis. Am J Hum Genet 2004;74:188-191. (Pubitemid 38085251)
225. Jin Y, Birlea SA, Fain PR, Spritz RA. Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. J Invest Dermatol 2007;127:2558-2562. (Pubitemid 47585070)
226. Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl JMed 2007;356:1216-1225. (Pubitemid 46465597)
227. D'Osualdo A, Reed JC.NLRP1, a regulator of innate immunity associated with vitiligo. Pigment Cell Melanoma Res 2012;25:5-8.
228. Tu CX, Gu JS, Lin XR. Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 2003;31:73-78.
229. Tanabe T, Ishige I, Suzuki Y, et al. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophys Acta 2006;1762:794-801. (Pubitemid 44403051)
230. Hysi P, Kabesch M, Moffatt MF, et al. NOD1 variation, immunoglobulin E and asthma. Hum Mol Genet 2005;14:935-941. (Pubitemid 40533104)
231. Weidinger S, Klopp N, Rummler L, et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J Allergy Clin Immunol 2005;116:177-184. (Pubitemid 40909765)
232. Bontron S, Steimle V, Ucla C, et al. Two novel mutations in the MHC class II transactivator CIITA in a second patient from MHC class II deficiency complementation group A. Hum Genet 1997;99:541-546. (Pubitemid 27152107)
233. Cressman DE, Chin KC, Taxman DJ, Ting JP. A defect in the nuclear translocation of CIITA causes a formof type II bare lymphocyte syndrome. Immunity 1999;10:163-171. (Pubitemid 29115622)
234. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993;75:135-146. (Pubitemid 23306027)
235. Zhou H, Glimcher LH. Human MHC class II gene transcription directed by the carboxyl terminus of CIITA, one of the defective genes in type II MHC combined immune deficiency. Immunity 1995;2:545-553.
236. Krawczyk M, ReithW. Regulation ofMHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. Tissue Antigens 2006;67:183-197. (Pubitemid 43383366)
237. ReithW,Mach B.The bare lymphocyte syndrome and the regulation ofMHCexpression. Annu Rev Immunol 2001;19:331-373. (Pubitemid 32368039)
238. Swanberg M, Lidman O, Padyukov L, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis,multiple sclerosis andmyocardial infarction. Nat Genet 2005;37:486-494. (Pubitemid 40617276)
239. Baranzini SE,Wang J,Gibson RA, et al.Genome-wide association analysis of susceptibility and clinical phenotype inmultiple sclerosis. HumMol Genet 2009;18:767-778.
240. Jeru I, Duquesnoy P, Fernandes-Alnemri T, et al. Mutations in NALP12 cause hereditary periodic fever syndromes. Proc Natl Acad Sci USA 2008;105:1614-1619. (Pubitemid 351346563)
241. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a metaanalysis. Gut 2001;48:526-535. (Pubitemid 32234798)
242. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994;35:950-954.
243. Chen GY, Nunez G. Inflammasomes in intestinal inflammation and cancer. Gastroenterology 2011;141:1986-1999.
244. Zaki MH, Lamkanfi M, Kanneganti TD. Inflammasomes and Intestinal Tumorigenesis.DrugDiscov Today DisMech 2011;8:e71-e78.
245. Kutikhin AG. Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. HumImmunol 2011;72:955-968.
246. Papaconstantinou I, Theodoropoulos G, Gazouli M, et al. Association between mutations in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer 2005;114: 433-435. (Pubitemid 40279965)
247. Mockelmann N, von Schonfels W, Buch S, et al. Investigation of innate immunity genes CARD4, CARD8 and CARD15 as germline susceptibility factors for colorectal cancer. BMC Gastroenterol 2009;9:79.
248. Alhopuro P, Ahvenainen T, Mecklin JP, et al. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res 2004;64:7245-7247. (Pubitemid 39372060)
249. Tuupanen S, Alhopuro P,Mecklin JP, et al. No evidence for association of NOD2 R702W and G908R with colorectal cancer. Int J Cancer 2007;121:76-79. (Pubitemid 46753853)
250. VermaD, Bivik C, Farahani E, et al. Inflammasomepolymorphisms confer susceptibility to sporadic malignantmelanoma. Pigment CellMelanoma Res 2012;25:506-513.
251. Murdoch S, Djuric U,Mazhar B, et al.Mutations in NALP7 cause recurrent hydatidiformmoles and reproductive wastage in humans. Nat Genet 2006;38:300-302.
252. Qian J, Deveault C, Bagga R, et al.Women heterozygous for NALP7/NLRP7mutations are at risk for reproductive wastage: report of two novelmutations. HumMutat 2007;28:741.
253. Wang CM, Dixon PH, Decordova S, et al. Identification of 13 novel NLRP7mutations in 20 families with recurrent hydatidiform mole; missense mutations cluster in the leucine-rich region. J Med Genet 2009;46:569-575.
254. Stolk L, Perry JR,Chasman DI, et al.Meta-analyses identify 13 loci associatedwith age atmenopause and highlight DNA repair and immune pathways. Nat Genet 2012;44:260-268.
255. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in > 80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation 2011;123: 731-738.
256. Dehghan A, Yang Q, Peters A, et al. Association of novel genetic Loci with circulating fibrinogen levels: a genome-wide association study in 6 population-based cohorts. Circ Cardiovasc Genet 2009;2:125-133.
257. Gieger C, Radhakrishnan A, Cvejic A, et al. New gene functions in megakaryopoiesis and platelet formation. Nature 2011;480:201-208.
258. Bergen SE, O'Dushlaine CT, Ripke S, et al. Genome-wide association study in a Swedish population yields support for greater CNV andMHCinvolvement in schizophrenia comparedwith bipolar disorder.Mol Psychiatry 2012;17:880-886.
259. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis ResTher 2007;9:R28.
260. Tran AP, Edelman J. Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 2011;14:e33-37.
261. Kingsbury SR, Conaghan PG, McDermott MF.The role of the NLRP3 inflammasome in gout. J Inflamm Res 2011;4:39-49.
262. Delaloye J, Roger T, Steiner-Tardivel QG, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009;5:e1000480.
263. Allen IC, Scull MA, Moore CB, et al.The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009;30:556-565.
264. Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellularM2 ion channel. Nat Immunol 2010;11:404-410.
265. Thomas PG, Dash P, Aldridge JR, Jr. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009;30: 566-575.
266. Sabbah A, Chang TH, Harnack R, et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009;10:1073-1080.
267. Gross O, Poeck H, BscheiderM, et al. Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defence. Nature 2009;459:433-436.
268. Hise AG, Tomalka J,Ganesan S, et al. An essential role for the NLRP3 inflammasomein host defense against the human fungal pathogen Candida albicans. Cell HostMicrobe 2009;5:487-497.
269. Said-Sadier N, Padilla E, Langsley G, Ojcius DM. Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase. PLoS One 2010;5:e10008.
270. Joly S,Ma N, Sadler JJ, et al. Cutting edge: Candida albicans hyphae formation triggers activation of the Nlrp3 inflammasome. J Immunol 2009;183:3578-3581.
271. Dostert C, Guarda G, Romero JF, et al.Malarial hemozoin is aNalp3 inflammasome activating danger signal. PLoS One 2009;4:e6510.
272. Shio MT, Eisenbarth SC, Savaria M, et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009;5:e1000559.
273. Reimer T, Shaw MH, Franchi L, et al. Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol 2010;40:764-769.
274. Ritter M, Gross O, Kays S, et al. Schistosoma mansoni triggers Dectin-2, which activates the Nlrp3 inflammasome and alters adaptive immune responses. Proc Natl Acad Sci USA 2010;107: 20459-20464.
275. Poeck H, Bscheider M, Gross O, et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 beta production. Nature immunology 2010;11:63-69.
276. Chopy D, Pothlichet J, Lafage M, et al. Ambivalent role of the innate immune response in rabies virus pathogenesis. J Virol 2011;85:6657-6668.
277. Satoh T, Kato H, Kumagai Y, et al. LGP2 is a positive regulator of RIG-I-and MDA5-mediated antiviral responses. Proc Natl Acad Sci USA 2010;107:1512-1517.
278. Venkataraman T, Valdes M, Elsby R, et al. Loss of DExD/H box RNA helicase LGP2 manifests disparate antiviral responses. J Immunol 2007;178:6444-6455. (Pubitemid 46717428)
279. Onoguchi K, Yoneyama M, Fujita T. Retinoic acid-inducible gene-I-like receptors. J Interferon Cytokine Res 2011;31:27-31.
280. Onoguchi K,YoneyamaM,Takemura A, et al.Viral infections activate types I andIII interferon genes through a commonmechanism. J Biol Chem 2007;282:7576-7581. (Pubitemid 47093699)
281. Hall JC, Rosen A. Type I interferons: crucial participants in disease amplification in autoimmunity. Nat Rev Rheumatol 2010;6:40-49.
282. Axtell RC, Raman C. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev 2012;248:23-35.
283. Gough DJ, Messina NL, Clarke CJ, et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012;36:166-174.
284. Pothlichet J, Burtey A, Kubarenko AV, et al. Study of human RIG-I polymorphisms identifies two variants with an opposite impact on the antiviral immune response. PLoS One 2009;4:e7582.
285. Shigemoto T, Kageyama M, Hirai R, et al. Identification of loss of function mutations in human genes encoding RIG-I and MDA5: implications for resistance to type I diabetes. J Biol Chem 2009;284:13348-13354.
286. Hu J,Nistal-Villan E, Voho A, et al. A common polymorphism in the caspase recruitment domain of RIG-Imodifies the innateimmune response of human dendritic cells. JImmunol 2010;185:424-432.
287. Ovsyannikova IG, Haralambieva IH, Dhiman N, et al. Polymorphisms in the vitamin A receptor and innate immunity genes influence the antibody response to rubella vaccination. J Infect Dis 2010;201:207-213.
288. Chistiakov DA. Interferon inducedwith helicase C domain 1 (IFIH1) and virus-induced autoimmunity: a review. Viral Immunol 2010;23:3-15.
289. Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006;38:617-619. (Pubitemid 43927300)
290. Concannon P, Onengut-Gumuscu S, Todd JA, et al. A human type 1 diabetes susceptibility locus maps to chromosome 21q22.3. Diabetes 2008;57:2858-2861.
291. Liu S,WangH, Jin Y, et al. IFIH1 polymorphisms are significantly associatedwith type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. HumMol Genet 2009;18:358-365.
292. Barrett JC, ClaytonDG, Concannon P, et al.Genome-wide association study andmeta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 2009;41:703-707.
293. Nejentsev S, Walker N, Riches D, et al. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009;324:387-389.
294. Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42:985-990.
295. Robinson T, Kariuki SN, Franek BS, et al. Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-alpha and serologic autoimmunity in lupus patients. J Immunol 2011;187:1298-1303.
296. Gono T, Kawaguchi Y, Sugiura T, et al. Interferon-induced helicase (IFIH1) polymorphismwith systemic lupus erythematosus and dermatomyositis/ polymyositis.Mod Rheumatol 2010;20:466-470.
297. Gateva V, Sandling JK,HomG, et al.Alarge-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 2009;41:1228-1233.
298. Ferreira RC, Pan-HammarstromQ, Graham RR, et al. Association of IFIH1 and other autoimmunity risk alleles with selective IgA deficiency. Nat Genet 2010;42:777-780.
299. Downes K, Pekalski M, AngusKL, et al. Reduced expression of IFIH1 is protective for type 1 diabetes. PLoS One 2010;5.
300. JaidaneH, Sauter P, Sane F, et al. Enteroviruses and type 1 diabetes: towards a better understanding of the relationship. RevMed Virol 2010;20:265-280.
301. Colli ML, Moore F, Gurzov EN, et al. MDA5 and PTPN2, two candidate genes for type 1 diabetes, modify pancreatic beta-cell responses to the viral by-product double-stranded RNA. Hum Mol Genet 2010;19:135-146.
302. McCartney SA, VermiW, Lonardi S, et al. RNA sensor-induced type I IFN prevents diabetes caused by a beta cell-tropic virus in mice. J Clin Invest 2011;121:1497-1507.
303. Pothlichet J, Niewold TB, Vitour D, et al. A loss-of-function variant of the antiviralmoleculeMAVS is associated with a subset of systemic lupus patients. EMBOMolMed 2011;3:142-152.
304. Liu X, Jiao Y, Wen X, et al. Possible association of VISA gene polymorphisms with susceptibility to systemic lupus erythematosus in Chinese population.Mol Biol Rep 2011;38:4583-4588.
305. Wang Y, Zhang HX, Sun YP, et al. Rig-I-/-mice develop colitis associated with downregulation of G alpha i2. Cell Res 2007;17:858-868. (Pubitemid 47585114)
306. Funke B, Lasitschka F, Roth W, et al. Selective downregulation of retinoic acid-inducible gene I within the intestinal epithelial compartment in Crohn's disease. Inflamm Bowel Dis 2011;17:1943-1954.
307. Gajewski TF, FuertesMB, Woo SR. Innate immune sensing of cancer: clues from an identified role for type I IFNs. Cancer Immunol Immunother 2012;61:1343-1347.
308. Sgorbissa A, Brancolini C. IFNs, ISGylation and cancer: Cui prodest? Cytokine Growth Factor Rev 2012;23:307-314.
309. ChoubeyD. Interferon-inducible Ifi200-family genes as modifiers of lupus susceptibility. Immunol Lett 2012;147:10-17.
310. Keating SE, Baran M, Bowie AG. Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol 2011;32:574-581.
311. Theofilopoulos AN, Kono DH, Beutler B, Baccala R. Intracellular nucleic acid sensors and autoimmunity. J Interferon Cytokine Res 2011;31:867-886.
312. Fernandes-Alnemri T, Yu JW, Datta P, et al. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 2009;458:509-513.
313. Burckstummer T, Baumann C, Bluml S, et al. An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome. Nature immunology 2009;10: 266-272.
314. Roberts TL, Idris A, Dunn JA, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science 2009;323:1057-1060.
315. Zhernakova A, Stahl EA, Trynka G, et al. Meta-analysis of genome-wide association studies in celiac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci. PLoS Genet 2011;7:e1002004.
316. Stene LC, Rewers M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the enterovirus link to type 1 diabetes: critical review of human studies. Clin Exp Immunol 2012;168:12-23.
317. Coppieters KT, Wiberg A, Tracy SM, vonHerrath MG. Immunology in the clinic review series: focus on type 1 diabetes and viruses: the role of viruses in type 1 diabetes: a difficult dilemma. Clin Exp Immunol 2012;168:5-11.
318. Lind K, Huhn MH, Flodstrom-Tullberg M. Immunology in the clinic review series; focus on type 1 diabetes and viruses: the innate immune response to enteroviruses and its possible role in regulating type 1 diabetes. Clin Exp Immunol 2012;168:30-38.
319. Grieco FA, Sebastiani G, Spagnuolo I, et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: how viral infections modulate beta cell function. Clin Exp Immunol 2012;168:24-29.
320. Hober D, Sane F, Jaidane H, et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: role of antibodies enhancing the infection with Coxsackievirus-B in the pathogenesis of type 1 diabetes. Clin Exp Immunol 2012;168:47-51.
321. Jaidane H, Sane F, Hiar R, et al. Immunology in the clinic review series; focus on type 1 diabetes and viruses: enterovirus, thymus and type 1 diabetes pathogenesis. Clin Exp Immunol 2012;168: 39-46.
322. Draborg AH, Duus K, Houen G. Epstein-Barr virus and systemic lupus erythematosus. Clin Dev Immunol 2012;2012:370516.
323. Pavlovic M, Kats A, Cavallo M, Shoenfeld Y. Clinical and molecular evidence for association of SLE with parvovirus B19. Lupus 2010;19:783-792.
324. Bouma G, Strober W.Theimmunological and genetic basis of inflammatory bowel disease.Nat Rev Immunol 2003;3:521-533. (Pubitemid 37328672)
325. Ireton RC, Gale M, Jr. RIG-I Like Receptors in Antiviral Immunity and Therapeutic Applications. Viruses 2011;3:906-919.
326. Cheng YS, Xu F. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biol Ther 2011;10:1219-1223.
327. Engel AL,Holt GE, Lu H.Thepharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Expert Rev Clin Pharmacol 2011;4:275-289.
328. Krishnan J, Lee G, Choi S. Drugs targeting Toll-like receptors. Arch PharmRes 2009;32:1485-1502.
329. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 2011;29:3341-3355.
330. Ma MJ, Xie LP, Wu SC, et al. Toll-like receptors, tumor necrosis factor-alpha, and interleukin-10 gene polymorphisms in risk of pulmonary tuberculosis and disease severity. Hum Immunol 2010;71:1005-1010.
331. Taylor BD, Darville T, Ferrell RE, et al. Variants in toll-like receptor 1 and 4 genes are associated with Chlamydia trachomatis among women with pelvic inflammatory disease. J Infect Dis 2012;205:603-609.
332. Lee JS, Park HK, Suh JS, et al. Toll-like receptor 1 gene polymorphisms in childhood IgA nephropathy: a case-control study in the Korean population. Int J Immunogenet 2011;38:133-138.
333. Barnholtz-Sloan JS, Shetty PB, Guan X, et al. FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis 2010;31:1417-1423.
334. Purdue MP, Lan Q,Wang SS, et al. A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma. Carcinogenesis 2009;30:275-281.
335. StevensVL,HsingAW,Talbot JT, et al.Genetic variation in the toll-like receptor gene cluster (TLR10-TLR1-TLR6) and prostate cancer risk. Int J Cancer 2008;123:2644-2650.
336. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007;39:645-649. (Pubitemid 46676108)
337. Lindstrom S, Hunter DJ, Gronberg H, et al. Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies. Cancer Epidemiol Biomarkers Prev 2010;19:873-876.
338. Chen YC, Giovannucci E, Kraft P, et al. Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1982-1989. (Pubitemid 47621171)
339. Sun J,Wiklund F, Zheng SL, et al. Sequence variants in Toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst 2005;97:525-532. (Pubitemid 40590434)
340. Sivula J, Cordova ZM, Tuimala J, et al. Toll-like receptor gene polymorphisms confer susceptibility to graft-versus-host disease in allogenic
341. Nischalke HD, Coenen M, Berger C, et al.The toll-like receptor 2 (TLR2)-196 to-174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer 2012;130:1470-1475.
342. Park CS, Cho JH, Park YJ. Toll-like receptor 2 gene polymorphisms in a Korean population: association with chronic rhinosinusitis. Otolaryngol Head Neck Surg 2011;144:96-100.
343. Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS ImmunolMedMicrobiol 2001;31:53-58.
344. Lorenz E, Mira JP, Cornish KL, et al. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000;68:6398-6401.
345. Moore CE, Segal S, Berendt AR, et al. Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus. Clin Diagn Lab Immunol 2004;11:1194-1197. (Pubitemid 39540867)
346. Pandey S,Mittal RD, SrivastavaM, et al. Impact of Toll-like receptors [TLR] 2 (-196 to-174 del) and TLR 4 (Asp299Gly,Thr399Ile) in cervical cancer susceptibility inNorth Indian women.GynecolOncol 2009;114:501-505.
347. Nieters A, Beckmann L, Deeg E, Becker N. Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun 2006;7:615-624. (Pubitemid 46242365)
348. Boraska Jelavic T, BarisicM, Drmic Hofman I, et al.Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer. Clin Genet 2006;70:156-160. (Pubitemid 44028102)
349. Srivastava K, Srivastava A,Kumar A,Mittal B. Significant association between toll-like receptor gene polymorphisms and gallbladder cancer. Liver Int 2010;30:1067-1072.
350. Tahara T, Arisawa T,Wang F, et al. Toll-like receptor 2-196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007;98:1790-1794. (Pubitemid 47487917)
351. Dzumhur A, Zibar L, Wagner J, et al. Association studies of gene polymorphisms in toll-like receptors 2 and 4 in Croatian patients with acute myocardial infarction. Scand J Immunol 2012;75:517-523.
352. Maldonado-Bernal C, Trejo-dela OA, Sanchez-Contreras ME, et al. Low frequency of Toll-like receptors 2 and 4 gene polymorphisms inMexican patients and their associationwith type 2 diabetes. Int J Immunogenet 2011;38:519-523.
353. Yang CA, Raftery MJ, Hamann L, et al. Association of TLR3- hyporesponsiveness and functional TLR3 L412F polymorphism with recurrent herpes labialis. Hum Immunol 2012;73:844-851.
354. Genc MR, Vardhana S,DelaneyML, et al. Relationship between a toll-like receptor-4 gene polymorphism, bacterial vaginosis-related flora and vaginal cytokine responses in pregnant women. Eur J Obstet Gynecol Reprod Biol 2004;116:152-156. (Pubitemid 39195125)
355. Goepfert AR, Varner M, Ward K, et al. Differences in inflammatory cytokine and Toll-like receptor genes and bacterial vaginosis in pregnancy. Am J Obstet Gynecol 2005;193:1478-1485. (Pubitemid 41395120)
356. RezazadehM, Hajilooi M, Rafiei A, et al. TLR4 polymorphism in Iranian patients with brucellosis. J Infect 2006;53:206-210. (Pubitemid 44227806)
357. van der Graaf CA, Netea MG, Drenth IP, et al. Candida-specific interferon-gamma deficiency and toll-like receptor polymorphisms in patients with chronicmucocutaneous candidiasis. Neth JMed 2003;61:365-369.
358. Morre SA, Murillo LS, Spaargaren J, et al. Role of the toll-like receptor 4 Asp299Gly polymorphism in susceptibility to Candida albicans infection. J Infect Dis 2002;186:1377-1379; author reply 1379. (Pubitemid 35193023)
359. Montes AH, Asensi V, Alvarez V, et al. The Toll-like receptor 4 (Asp299Gly) polymorphism is a risk factor for Gram-negative and haematogenous osteomyelitis. Clin Exp Immunol 2006;143: 404-413.
360. Mockenhaupt FP, Hamann L, von Gaertner C, et al. Common polymorphisms of toll-like receptors 4 and 9 are associated with the clinicalmanifestation ofmalaria during pregnancy. J Infect Dis 2006;194:184-188. (Pubitemid 44087189)
361. Allen A, Obaro S, Bojang K, et al. Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr Infect Dis J 2003;22:1018-1019. (Pubitemid 37445083)
362. Biebl A, Muendlein A, Kazakbaeva Z, et al. CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients. PLoS One 2009;4:e7374.
363. Smirnova I, Mann N, Dols A, et al. Assay of locus-specific genetic load implicates rare Tolllike receptor 4 mutations in meningococcal susceptibility. Proc Natl Acad Sci USA 2003;100: 6075-6080. (Pubitemid 36576933)
364. Brett PM, Zygogianni P, Griffiths GS, et al. Functional gene polymorphisms in aggressive and chronic periodontitis. J Dent Res 2005;84:1149-1153. (Pubitemid 43827783)
365. Kinane DF, Shiba H, Stathopoulou PG, et al. Gingival epithelial cells heterozygous for Toll-like receptor 4 polymorphisms Asp299Gly and Thr399ile are hypo-responsive to Porphyromonas gingivalis. Genes Immun 2006;7:190-200.
366. LaineML,Morre SA,Murillo LS, et al. CD14 and TLR4 gene polymorphisms in adult periodontitis. J Dent Res 2005;84:1042-1046. (Pubitemid 43828153)
367. D'Aiuto F, Parkar M, Brett PM, et al. Gene polymorphisms in pro-inflammatory cytokines are associated with systemic inflammation in patients with severe periodontal infections. Cytokine 2004;28:29-34. (Pubitemid 39165618)
368. FolwacznyM, Glas J, Torok HP, et al. Toll-like receptor (TLR) 2 and 4mutations in periodontal disease. Clin Exp Immunol 2004;135:330-335. (Pubitemid 38177975)
369. Balistreri CR, Candore G, Lio D, et al. Role of TLR4 receptor polymorphisms in Boutonneuse fever. Int J Immunopathol Pharmacol 2005;18:655-660.
370. Liadaki K, Petinaki E, Skoulakis C, et al. Toll-like receptor 4 gene (TLR4), but not TLR2, polymorphisms modify the risk of tonsillar disease due to Streptococcus pyogenes and Haemophilus influenzae. Clin Vaccine Immunol 2011;18:217-222.
371. Landi S, Gemignani F, Bottari F, et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed 2006;5:15.
372. Tsilidis KK, Helzlsouer KJ, Smith MW, et al. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 2009;20:1739-1751.
373. Forrest MS, Skibola CF, Lightfoot TJ, et al. Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma. Br J Haematol 2006;134:180-183. (Pubitemid 43893909)
374. Ture-Ozdemir F, Gazouli M, Tzivras M, et al. Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Anticancer Res 2008;28:3697-3700.
375. Ohara T, Morishita T, Suzuki H, Hibi T. Heterozygous Thr 135 Ala polymorphism at leucine-rich repeat (LRR) in genomic DNA of toll-like receptor 4 in patients with poorly-differentiated gastric adenocarcinomas. Int JMolMed 2006;18:59-63.
376. Santini D, Angeletti S, Ruzzo A, et al. Toll-like receptor 4 Asp299Gly andThr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes. Clin Exp Immunol 2008;154:360-364.
377. Hold GL, Rabkin CS, Chow WH, et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007;132:905-912. (Pubitemid 46440859)
378. Hellmig S, FischbachW,Goebeler-KolveME, et al. Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. Leuk Lymphoma 2005;46:869-872. (Pubitemid 40965398)
379. Achyut BR, Ghoshal UC, Moorchung N, Mittal B. Association of Toll-like receptor-4 (Asp299Gly and Thr399Ileu) gene polymorphisms with gastritis and precancerous lesions. Hum Immunol 2007;68:901-907. (Pubitemid 350235728)
380. Hishida A, Matsuo K, Goto Y, et al. Toll-like receptor 4 +3725 G/C polymorphism, Helicobacter pylori seropositivity, and the risk of gastric atrophy and gastric cancer in Japanese. Helicobacter 2009;14:47-53.
381. Rigoli L, Di Bella C, Fedele F, et al. TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis. Anticancer Res 2010;30:513-517.
382. Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004;64:2918-2922. (Pubitemid 38500633)
383. Chen YC,Giovannucci E, LazarusR, et al. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res 2005;65:11771-11778. (Pubitemid 41821739)
384. Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other immune response-and obesity-related genes with prostate cancer in CLUE II. Prostate 2009;69:874-885.
385. Cheng I, Plummer SJ, CaseyG,Witte JS. Toll-like receptor 4 genetic variation and advanced prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2007;16:352-355. (Pubitemid 46383358)
386. Song J, KimDY, KimCS, et al.The association between Toll-like receptor 4 (TLR4) polymorphisms and the risk of prostate cancer in Korean men. Cancer Genet Cytogenet 2009;190:88-92.
387. Weyrich P, Staiger H, Stancakova A, et al.The D299G/T399I Toll-like receptor 4 variant associates with body and liver fat: results fromthe TULIP and METSIM Studies. PLoS One 2010;5:e13980.
388. Sampath V, Garland JS, LeM, et al. A TLR5 (g.1174C>T) variant that encodes a stop codon (R392X) is associated with bronchopulmonary dysplasia. Pediatr Pulmonol 2012;47:460-468.
389. Cerhan JR, Ansell SM, Fredericksen ZS, et al. Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. Blood 2007;110:4455-4463. (Pubitemid 351377812)
390. Monroy CM, Cortes AC, Lopez MS, et al. Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes.Mol Carcinog 2011;50:36-46.
391. Sahingur SE, Xia XJ, Gunsolley J, et al. Single nucleotide polymorphisms of pattern recognition receptors and chronic periodontitis. J Periodontal Res 2011;46:184-192.
392. Chen KH, Zeng L, GuW, et al. Polymorphisms in the toll-like receptor 9 gene associated with sepsis andmultiple organ dysfunction aftermajor blunt trauma. Br J Surg 2011;98:1252-1259.
393. Su SL, Yang HY, Lee CH, et al.The (-1486T/C) promoter polymorphism of the TLR-9 gene is associated with end-stage knee osteoarthritis in a Chinese population. J Orthop Res 2012;30:9-14.
394. Hold GL, Rabkin CS, GammonMD, et al. CD14-159C/T and TLR9-1237T/C polymorphisms are not associated with gastric cancer risk in Caucasian populations. Eur J Cancer Prev 2009;18:117-119.
395. Mollaki V, Georgiadis T, Tassidou A, et al. Polymorphisms and haplotypes in TLR9 andMYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study. J HumGenet 2009;54:655-659.
396. Sklar P, Ripke S, Scott LJ, et al. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet 2011;43:977-983.
397. Lu KC, Yang HY, Lin YF, et al.The T-1237C polymorphism of the Toll-like receptor-9 gene is associatedwith chronic kidney disease in aHanChinese population. Tohoku J ExpMed 2011;225:109-116.
398. Lammers KM, Ouburg S, Morre SA, et al. Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol 2005;11:7323-7329. (Pubitemid 43137684)
399. Rajaraman P, Brenner AV,Neta G, et al. Risk ofmeningioma and common variation in genes related to innate immunity. Cancer Epidemiol Biomarkers Prev 2010;19:1356-1361.
400. Newton-Cheh C, Eijgelsheim M, Rice KM, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 2009;41:399-406.
401. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 2010;42:504-507.
402. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-1093. (Pubitemid 47014426)
403. Stanescu HC, Arcos-BurgosM,Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl JMed 2011;364:616-626.
404. MiddelbergRP, FerreiraMA,Henders AK, et al.Genetic variants in LPL,OASL and TOMM40/APOEC1-C2-C4 genes are associated with multiple cardiovascular- related traits. BMC Med Genet 2011;12:123.
405. Tao S,Wang Z, Feng J, et al. A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants. Carcinogenesis 2012;33:598-603.
406. Kugathasan S, Baldassano RN, Bradfield JP, et al. Loci on 20q13 and 21q22 are associated with pediatric-onset inflammatory bowel disease. Nat Genet 2008;40:1211-1215.